U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H19N7O7S3.Na.H
Molecular Weight 541.557
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFMINOX SODIUM

SMILES

[H+].[Na+].[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSC[C@@H](N)C([O-])=O)OC)C([O-])=O

InChI

InChIKey=SBIDXLKJYJVQOE-YNJMIPHHSA-M
InChI=1S/C16H21N7O7S3.Na/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26;/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28);/q;+1/p-1/t8-,14-,16+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C16H19N7O7S3
Molecular Weight 517.56
Charge -2
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.toku-e.com/Cefminox-sodium-P646.aspx and http://www.ncbi.nlm.nih.gov/pubmed/9517922

Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. It is indicated in treatment of the following infections caused by sensitive bacteria: 1. Respiratory infections: Amygdalitis, circumtonsillar abscess, bronchitis, bronchiolitis, bronchiectasis (in fection), secondary infections of chronic respiratory diseases, pneumonia, and pulmonary suppuration; 2. Infection in urinary system: Nephropyelitis, cystitis; 3. Infections in abdominal cavity: Cholecystitis' angiocholitis'peritonitis; 4. Infections in pelvic cavity: Pelvic peritonitis, adnexitis, intrauterine infection, inflammation in pelvic dead space, and parametritis; 5. Septicaemia.

Originator

Curator's Comment: Sankyo Launched cefminox in 1995

Approval Year

PubMed

PubMed

TitleDatePubMed
Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers.
1994 Jan
In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
1998 Mar
Synthesis of cefminox by cell-free extracts of Streptomyces clavuligerus.
2000 Jan 15
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.
2014
In Vitro Analysis of Activities of 16 Antimicrobial Agents against Gram-Negative Bacteria from Six Teaching Hospitals in China.
2015
Patents

Sample Use Guides

Administration only for intravenous injection or intervenous drop injection. For intravenous injection: Cefminox sodium 1g (valence) can be dissolved in 200ml water for injection, and 5~10% glucose or 0.9% sodium chloride injection. For intervenous drop injection: Cefminox sodium 1g (valence) can be dissolved in 100~500ml 5~10% glucose or 0.9% sodium chloride injection. A drop innjection for 1~2 hours. Recommended dose for adults: 1g (valence) to be administrated twice a day; Adjusted according to the age and symptoms; In septicaemia, and refractory or severe infections, a total daily dosage of 6g (valence) is divided into 3~4 administrations. Recommended dose for children: 20mg (valence)/kg (body weight) to be administrated 3~ 4 times a day.
Route of Administration: Intravenous
In Vitro Use Guide
The MIC50 and MIC90 of cefminox against E. coli were 1.0 mg/L and 4.0 mg/L, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:39:21 GMT 2023
Edited
by admin
on Fri Dec 15 17:39:21 GMT 2023
Record UNII
YNM4DBJ3N8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFMINOX SODIUM
MART.   WHO-DD  
Common Name English
CEFMINOX SODIUM SALT ANHYDROUS [MI]
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((((2S)-2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, MONOSODIUM SALT, (6R,7S)-
Systematic Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((((2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, MONOSODIUM SALT, (6R-(6.ALPHA.,7.ALPHA.,7(S*)))-
Systematic Name English
CEFMINOX SODIUM [MART.]
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((2-(((2S)-2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, SODIUM SALT (1:1), (6R,7S)-
Systematic Name English
Cefminox sodium [WHO-DD]
Common Name English
CEFMINOX SODIUM SALT ANHYDROUS
MI  
Common Name English
SODIUM 7-(2-((S)-2-AMINO-2-CARBOXYETHYL)THIOACETAMIDO)-7-METHOXY-3-(1-METHYL-1H-TETRAZOL-5-YLTHIOMETHYL)-3-CEPHEM-4-CARBOXYLATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
Code System Code Type Description
FDA UNII
YNM4DBJ3N8
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
PUBCHEM
23663397
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
ChEMBL
CHEMBL1276342
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
SMS_ID
100000084985
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
EVMPD
SUB01119MIG
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
DRUG BANK
DBSALT001118
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
CAS
75498-96-3
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
NCI_THESAURUS
C98223
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID6048591
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
MESH
C046079
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
MERCK INDEX
m3198
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
CHEBI
31371
Created by admin on Fri Dec 15 17:39:21 GMT 2023 , Edited by admin on Fri Dec 15 17:39:21 GMT 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY